双PD-1与CTLA-4或KIR阻断联合方案治疗复发/难治性淋巴系统恶性肿瘤的1b期研究
这项1b期试验入组复发/难治性经典型霍奇金淋巴瘤(cHL)、非霍奇金淋巴瘤(NHL)或多发性骨髓瘤(MM)成人患者,分别接受纳武利尤单抗联合伊匹木单抗(nivo/ipi)或联合利瑞鲁单抗(nivo/liri)治疗。nivo/ipi组29%患者发生3-4级治疗相关不良事件,nivo/liri组为15%;cHL中ORR分别为74%和76%,CRR分别为23%和24%;B-NHL和T-NHL中ORR范围为9-22%,CRR为0-6%;MM无客观缓解。
要点
- cHL中nivo/ipi与nivo/liri的ORR分别为74%与76%,CRR分别为23%与24%。
- nivo/ipi组29%患者发生3-4级治疗相关不良事件,nivo/liri组为15%。
- B-NHL和T-NHL中ORR范围为9-22%,CRR为0-6%;MM无客观缓解。
核心结论
- 两种联合方案在cHL中均有活性,但nivo/ipi的毒性高于单用纳武利尤单抗的预期水平。
- 这些数据提示在所研究的疾病中,联合方案相比单用纳武利尤单抗未见有意义的疗效改善。
研究设计与样本
- 1b期试验入组复发/难治性经典型霍奇金淋巴瘤、非霍奇金淋巴瘤或多发性骨髓瘤成人患者。
- 65例患者接受nivo/ipi治疗,72例接受nivo/liri治疗,治疗至完全缓解、疾病进展或不可接受毒性。
- 主要终点为安全性与耐受性,次要终点包括总缓解率(ORR)、完全缓解率(CRR)、无进展生存和总生存。
主要发现
- nivo/ipi组29%患者发生3-4级治疗相关不良事件,nivo/liri组为15%。
- cHL中nivo/ipi的ORR为74%、CRR为23%,nivo/liri的ORR为76%、CRR为24%。
- B-NHL和T-NHL中ORR范围为9-22%,CRR为0-6%。
- 多发性骨髓瘤患者无客观缓解。
关键数值与推荐
- cHL中nivo/ipi的ORR为74%、CRR为23%,nivo/liri的ORR为76%、CRR为24%。
- nivo/ipi组3-4级治疗相关不良事件发生率为29%,nivo/liri组为15%。
- B-NHL和T-NHL中ORR范围为9-22%,CRR为0-6%。
临床怎么用
- 原文结论指出联合方案相比单用纳武利尤单抗在所研究疾病中未见有意义的疗效改善,未据此给出推荐。
局限性
- 原文结论指出nivo/ipi的毒性高于单用纳武利尤单抗的预期水平。
- 原文结论指出这些数据提示联合方案相比单用纳武利尤单抗未见有意义的疗效改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Simultaneously targeting other pathways could increase the activity of PD-1 blockade in lymphoid malignancies not sensitive to single-agent blockade. We explored the safety and efficacy of combined PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory (R/R) lymphoid malignancies. This phase 1b trial enrolled adult patients with R/R classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL), or multiple myeloma (MM). Patients received nivolumab plus ipilimumab (nivo/ipi) or lirilumab (nivo/liri) until complete response (CR), progression, or unacceptable toxicity. The primary endpoint was safety and tolerability, while secondary endpoints included overall (ORR) and CR rates (CRR), progression-free and overall survival. Sixty-five patients were treated with nivo/ipi, and 72 with nivo/liri. Twenty-nine percent of patients experienced grade 3-4 treatment-related adverse events with nivo/ipi, and 15% with nivo/liri. In cHL, ORR was 74% for nivo/ipi and 76% for nivo/liri, CRRs were 23% and 24%, respectively. In B-NHL and T-NHL, ORR range was 9-22% and CRR was 0-6%. No patient with MM had an objective response. While both combinations were active in cHL, the toxicity of nivo/ipi was higher than expected from nivolumab alone. These data suggest no meaningful improvement in the efficacy of the combinations over single-agent nivolumab in the diseases studied.
引用
- Armand P, Lesokhin A, Borrello I, et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2020. PMID: 32601377. doi:10.1038/s41375-020-0939-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。